In a study by Bai et al.., nanozymes capable of depleting cholesterol and disrupting lipid rafts were tested against a breast cancer cell line resulting in an increase in membrane fluidity and ferroptosis sensitivity of the cancer cells, via a mechanism involving downregulation of both GPX4 and FSP1 [54]. The gene discussed is AIFM2; the disease is cancer.